Characteristics predicting tuberculosis risk under tumor necrosis factor-α inhibitors: Report from a large multicenter cohort with high background prevalence

Journal of Rheumatology

Volumn 43, Issue 3, 2016, Pages 524-529

  Kisacik, Bunyamin ^a   Pamuk, Omer Nuri ^b   Onat, Ahmet Mesut ^a   Erer, Sait Burak ^c   Hatemi, Gulen ^c   Ozguler, Yesim ^c   Pehlivan, Yavuz ^d   Kilic, Levent ^e   Ertenli, Ihsan ^e   Can, Meryem ^f   Direskeneli, Haner ^g   Keser, Gökhan ^h   Oksel, Fahrettin ^h   Dalkilic, Ediz ^d   Yilmaz, Sedat ⁱ   Pay, Salih ⁱ   Balkarli, Ayse ^j   Cobankara, Veli ^j   Cetin, Gözde Yildirim ^k   Sayarlioglu, Mehmet ^l   Cefle, Ayse ^m   Yazici, Ayten ^m   Avci, Ali Berkant ⁿ   Terzioglu, Ender ⁿ   Ozbek, Suleyman ^o   Akar, Servet ^p   Gul, Ahmet ^c   more..

^a GAZIANTEP UNIVERSITY   (Turkey)

^b TRAKYA UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

^d ULUDAG UNIVERSITY   (Turkey)

^e HACETTEPE UNIVERSITY   (Turkey)

^f FATIH SULTAN MEHMET TRAINING AND RESEARCH HOSPITAL   (Turkey)

^g MARMARA UNIVERSITY   (Turkey)

^h EGE UNIVERSITY   (Turkey)

ⁱ GULHANE SCHOOL OF MEDICINE   (Turkey)

^j PAMUKKALE UNIVERSITY   (Turkey)

^k KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

^l ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^m KOCAELI UNIVERSITY   (Turkey)

ⁿ AKDENIZ UNIVERSITY   (Turkey)

^o CUKUROVA UNIVERSITY   (Turkey)

^p IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

more..

Author keywords

Tuberculosis reactivation isoniazid; Tumor necrosis factor A inhibitors

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; ISONIAZID; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR;

ADULT; AGE DISTRIBUTION; ANKYLOSING SPONDYLITIS; ARTICLE; BEHCET DISEASE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; INFECTION RISK; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PATHOGENESIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK FACTOR; SEX DIFFERENCE; SKIN TEST; TURKEY (REPUBLIC); ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; MIDDLE AGED; RISK; SPONDYLITIS, ANKYLOSING; TUBERCULOSIS;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; PREVALENCE; RISK; SPONDYLITIS, ANKYLOSING; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84959906308     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150177     Document Type: Article

References (26)

1. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology 2003;42:617-21.
2. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5.
3. Algood HM, Lin PL, Flynn JL. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 2005;41:189-93.
4. World Health Organization. Global tuberculosis report 2015. [Internet. Accessed November 4, 2015.] Available from: www.who.int/tb/publications/global-report/en
5. Olleros ML, Guler R, Corazza N, Vesin D, Eugster HP, Marchal G, et al. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin. J Immunol 2002;168:3394-401.
6. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029-35.
7. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
8. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-8.
9. Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008;58:1248-57.
10. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;8:2122-7.
11. Gómez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-61.
12. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al; BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8.
13. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al; Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60:1884-94.
14. Hetland ML. DANBIO: a nationwide registry of biological therapies in Denmark. Clin Exp Rheumatol 2005;23 Suppl 39:S205-7.
15. Pérez-Sola MJ, Torre-Cisneros J, Pérez-Zafrilla B, Carmona L, Descalzo MA, Gómez-Reino JJ; BIOBADASER Study Group. Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. Med Clin 2011;137:533-40.
16. Williams MP, Buchbinder R, March L, Lassere M. The Australian Rheumatology Association Database (ARAD). Semin Arthritis Rheum 2011;40:e2-3.
17. 6th International Congress on FMF and SAID 2010;L1.31. Cengiz M, Demirdaʇ F, Hatemi G, Seyahi E, Ozdogan H. The first degree relatives of FMF patients have similar mortality and morbidity rates compared to controls. [Internet. Accessed November 11, 2015.] Available from: fmf.igh.cnrs.fr/ISSAID/doc/Abstracts-Amsterdam-2010.pdf
18. Seyahi E, Ugurlu S, Seyahi N, Celik AF, Melikoglu M, Fresko I, et al. A survey of socioeconomic status in Behcet's Syndrome. Clin Exp Rheum 2004;22 Suppl 34: 88.
19. Hwang CH, Khan S, Ende N, Mangura BT, Reichman LB, Chou J. The HLA-A, -B, and -DR phenotypes and tuberculosis. Am Rev Respir Dis 1985;132:382-5.
20. Hafez M, el-Salab S, el-Shennawy F, Bassiony MR. HLA-antigens and tuberculosis in the Egyptian population. Tubercle 1985; 66:35-40.
21. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-5.
22. Denis B, Lefort A, Flipo RM, Tubach F, Lemann M, Ravaud P, et al; RATIO Group. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment. Clin Microbiol Infect 2008;14:183-6.
23. Sterling TR, Zhao Z, Khan A, Chaisson RE, Schluger N, Mangura B; Tuberculosis Trials Consortium. Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. Int J Tuberc Lung Dis 2006;10:542-9.
24. Walpola HC, Siskind V, Patel AM, Konstantinos A, Derhy P. Tuberculosis-related deaths in Queensland, Australia, 1989-1998: characteristics and risk factors. Int J Tuberc Lung Dis 2003; 7:742-50.
25. Silva DR, Menegotto DM, Schulz LF, Gazzana MB, Dalcin Pde T. Factors associated with mortality in hospitalized patients with newly diagnosed tuberculosis. Lung 2010;188:33-41.
26. Stagg HR, Zenner D, Harris RJ, Muñoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med 2014;161:419-28.